Does the media favor IMNM or RIGL?

In the previous week, Rigel Pharmaceuticals had 8 more articles in the media than Immunome. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 4 mentions for Immunome. Rigel Pharmaceuticals' average media sentiment score of 1.19 beat Immunome's score of 0.85 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, GRAL or RIGL?

Rigel Pharmaceuticals has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 23.24 -$408.35M -$9.75 N/A Rigel Pharmaceuticals $294.28M 2.84 $367.02M $16.32 2.76

Does the media refer more to GRAL or RIGL?

In the previous week, Rigel Pharmaceuticals had 10 more articles in the media than GRAIL. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 2 mentions for GRAIL. Rigel Pharmaceuticals' average media sentiment score of 1.19 beat GRAIL's score of 0.34 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rigel Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RIGL or ZLAB?

In the previous week, Rigel Pharmaceuticals had 10 more articles in the media than Zai Lab. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 2 mentions for Zai Lab. Rigel Pharmaceuticals' average media sentiment score of 1.19 beat Zai Lab's score of 0.74 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NRIX or RIGL?

In the previous week, Rigel Pharmaceuticals had 6 more articles in the media than Nurix Therapeutics. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 6 mentions for Nurix Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 1.19 beat Nurix Therapeutics' score of 1.11 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BEAM or RIGL?

In the previous week, Rigel Pharmaceuticals had 8 more articles in the media than Beam Therapeutics. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 4 mentions for Beam Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 1.19 beat Beam Therapeutics' score of 1.16 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rigel Pharmaceuticals (RIGL) Competitors

$45.11 -0.78 (-1.70%)

Closing price 04:00 PM Eastern

Extended Trading

$45.13 +0.02 (+0.04%)

As of 06:53 PM Eastern

Compare

RIGL vs. IMNM, GRAL, ZLAB, NRIX, and BEAM

Should you buy Rigel Pharmaceuticals stock or one of its competitors? Rigel Pharmaceuticals's main competitors and comparable companies include Immunome (IMNM), GRAIL (GRAL), Zai Lab (ZLAB), Nurix Therapeutics (NRIX), and Beam Therapeutics (BEAM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rigel Pharmaceuticals compare to Immunome?

Immunome (NASDAQ:IMNM) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Immunome's net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

In the previous week, Rigel Pharmaceuticals had 8 more articles in the media than Immunome. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 4 mentions for Immunome. Rigel Pharmaceuticals' average media sentiment score of 1.19 beat Immunome's score of 0.85 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunome has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Immunome presently has a consensus target price of $34.64, suggesting a potential upside of 23.66%. Rigel Pharmaceuticals has a consensus target price of $59.00, suggesting a potential upside of 30.79%. Given Rigel Pharmaceuticals' higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	458.41	-$212.39M	-$2.53	N/A
Rigel Pharmaceuticals	$294.28M	2.84	$367.02M	$16.32	2.76

44.6% of Immunome shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Rigel Pharmaceuticals beats Immunome on 11 of the 15 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 1.8% of GRAIL shares are held by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

GRAIL presently has a consensus target price of $67.78, indicating a potential downside of 11.49%. Rigel Pharmaceuticals has a consensus target price of $59.00, indicating a potential upside of 30.79%. Given Rigel Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Rigel Pharmaceuticals had 10 more articles in the media than GRAIL. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 2 mentions for GRAIL. Rigel Pharmaceuticals' average media sentiment score of 1.19 beat GRAIL's score of 0.34 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a net margin of 116.30% compared to GRAIL's net margin of -236.95%. Rigel Pharmaceuticals' return on equity of 22.95% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Rigel Pharmaceuticals has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	23.24	-$408.35M	-$9.75	N/A
Rigel Pharmaceuticals	$294.28M	2.84	$367.02M	$16.32	2.76

GRAIL has a beta of 3.24, indicating that its share price is 224% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

Summary

Rigel Pharmaceuticals beats GRAIL on 12 of the 14 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Zai Lab?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Rigel Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

In the previous week, Rigel Pharmaceuticals had 10 more articles in the media than Zai Lab. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 2 mentions for Zai Lab. Rigel Pharmaceuticals' average media sentiment score of 1.19 beat Zai Lab's score of 0.74 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.84	$367.02M	$16.32	2.76
Zai Lab	$460.16M	6.34	-$175.54M	-$1.71	N/A

Rigel Pharmaceuticals has a net margin of 116.30% compared to Zai Lab's net margin of -41.86%. Rigel Pharmaceuticals' return on equity of 22.95% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
Zai Lab	-41.86%	-27.43%	-16.72%

Rigel Pharmaceuticals currently has a consensus target price of $59.00, indicating a potential upside of 30.79%. Zai Lab has a consensus target price of $40.20, indicating a potential upside of 56.79%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts clearly believe Zai Lab is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 4.9% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Rigel Pharmaceuticals beats Zai Lab on 10 of the 15 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Nurix Therapeutics' net margin of -928.44%. Rigel Pharmaceuticals' return on equity of 22.95% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Nurix Therapeutics presently has a consensus price target of $34.21, suggesting a potential upside of 30.24%. Rigel Pharmaceuticals has a consensus price target of $59.00, suggesting a potential upside of 30.79%. Given Rigel Pharmaceuticals' higher possible upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	32.46	-$264.46M	-$3.45	N/A
Rigel Pharmaceuticals	$294.28M	2.84	$367.02M	$16.32	2.76

In the previous week, Rigel Pharmaceuticals had 6 more articles in the media than Nurix Therapeutics. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 6 mentions for Nurix Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 1.19 beat Nurix Therapeutics' score of 1.11 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nurix Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Summary

Rigel Pharmaceuticals beats Nurix Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Beam Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Rigel Pharmaceuticals has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	20.94	-$79.99M	-$0.86	N/A
Rigel Pharmaceuticals	$294.28M	2.84	$367.02M	$16.32	2.76

In the previous week, Rigel Pharmaceuticals had 8 more articles in the media than Beam Therapeutics. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 4 mentions for Beam Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 1.19 beat Beam Therapeutics' score of 1.16 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Beam Therapeutics' net margin of -54.75%. Rigel Pharmaceuticals' return on equity of 22.95% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Beam Therapeutics presently has a consensus target price of $49.00, indicating a potential upside of 72.96%. Rigel Pharmaceuticals has a consensus target price of $59.00, indicating a potential upside of 30.79%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Beam Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Rigel Pharmaceuticals beats Beam Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Rigel Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RIGL vs. The Competition

Export

Metric	Rigel Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$849.06M	$3.99B	$7.29B	$12.71B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	11.71	11.75	271.38	24.10
Price / Sales	2.84	1,398.89	638.99	90.03
Price / Cash	6.81	44.94	29.03	36.90
Price / Book	2.09	17.26	11.18	6.40
Net Income	$367.02M	-$22.72M	$3.46B	$348.28M
7 Day Performance	6.27%	2.89%	1.98%	0.91%
1 Month Performance	22.78%	9.74%	7.32%	5.10%
1 Year Performance	8.70%	54.81%	24.76%	16.16%

Rigel Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RIGL Rigel Pharmaceuticals	4.5615 of 5 stars	$45.11 -1.7%	$59.00 +30.8%	+10.6%	$849.06M	$294.28M	2.76	160	Positive News
IMNM Immunome	2.4212 of 5 stars	$27.40 +0.7%	$34.64 +26.4%	+176.9%	$3.09B	$6.94M	N/A	40
GRAL GRAIL	0.922 of 5 stars	$69.95 +3.1%	$67.78 -3.1%	+132.3%	$3.03B	$147.17M	N/A	1,360	Positive News
ZLAB Zai Lab	2.4001 of 5 stars	$25.64 -1.0%	$40.20 +56.8%	-25.8%	$2.95B	$460.16M	N/A	1,784	Gap Down
NRIX Nurix Therapeutics	3.1235 of 5 stars	$27.17 +0.4%	$34.21 +25.9%	+163.5%	$2.81B	$83.98M	N/A	300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RIGL) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. IMNM, GRAL, ZLAB, NRIX, and BEAM

How does Rigel Pharmaceuticals compare to Immunome?

Summary

How does Rigel Pharmaceuticals compare to GRAIL?

Summary

How does Rigel Pharmaceuticals compare to Zai Lab?

Summary

How does Rigel Pharmaceuticals compare to Nurix Therapeutics?

Summary

How does Rigel Pharmaceuticals compare to Beam Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. IMNM, GRAL, ZLAB, NRIX, and BEAM

How does Rigel Pharmaceuticals compare to Immunome?

Is IMNM or RIGL more profitable?

Does the media favor IMNM or RIGL?

Which has more volatility and risk, IMNM or RIGL?

Do analysts prefer IMNM or RIGL?

Which has higher earnings and valuation, IMNM or RIGL?

Do institutionals and insiders hold more shares of IMNM or RIGL?

Summary

How does Rigel Pharmaceuticals compare to GRAIL?

Do insiders & institutionals have more ownership in GRAL or RIGL?

Do analysts prefer GRAL or RIGL?

Does the media refer more to GRAL or RIGL?

Is GRAL or RIGL more profitable?

Which has stronger valuation & earnings, GRAL or RIGL?

Which has more volatility & risk, GRAL or RIGL?

Summary

How does Rigel Pharmaceuticals compare to Zai Lab?

Which has more volatility & risk, RIGL or ZLAB?

Does the media prefer RIGL or ZLAB?

Which has preferable earnings & valuation, RIGL or ZLAB?

Is RIGL or ZLAB more profitable?

Do analysts rate RIGL or ZLAB?

Do institutionals and insiders have more ownership in RIGL or ZLAB?

Summary

How does Rigel Pharmaceuticals compare to Nurix Therapeutics?

Is NRIX or RIGL more profitable?

Do analysts prefer NRIX or RIGL?

Which has stronger valuation & earnings, NRIX or RIGL?

Does the media refer more to NRIX or RIGL?

Do insiders and institutionals have more ownership in NRIX or RIGL?

Which has more risk & volatility, NRIX or RIGL?

Summary

How does Rigel Pharmaceuticals compare to Beam Therapeutics?

Which has more volatility & risk, BEAM or RIGL?

Which has preferable valuation and earnings, BEAM or RIGL?

Does the media prefer BEAM or RIGL?

Do insiders & institutionals believe in BEAM or RIGL?

Is BEAM or RIGL more profitable?

Do analysts rate BEAM or RIGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools